The FDA declined to approve Disc Medicine's bitopertin for erythropoietic protoporphyria on February 13, 2026, citing insufficient evidence linking biomarker reductions to clinical benefit. The company will pursue traditional approval using Phase 3 APOLLO trial data expected in Q4 2026.
The FDA issued a Complete Response Letter for bitopertin in erythropoietic protoporphyria, acknowledging the drug lowers PPIX levels but requiring Phase 3 APOLLO trial results to demonstrate clinical benefit before approval.
The FDA issued a Complete Response Letter for Disc Medicine's bitopertin New Drug Application for erythropoietic protoporphyria, requiring results from the ongoing Phase 3 APOLLO study before making an approval decision. Topline data is expected in Q4 2026.
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07387354 |
Pacritinib With Aza for Upfront Myelodysplastic Syndrome |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07364409 |
Autologous Transplantation of Human Cryopreserved Testis Tissue |
ACTIVE_NOT_RECRUITING | NA |
| NCT07257640 |
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia |
RECRUITING | PHASE1 |
| NCT07023692 |
Visual and Auditory Distraction for the Relief of Pain and Anxiety |
ENROLLING_BY_INVITATION | NA |
| NCT06857604 |
The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases |
RECRUITING | NA |
| NCT06809699 |
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation |
RECRUITING | PHASE1 |
| NCT06797375 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants |
COMPLETED | PHASE1 |
| NCT06795815 |
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease |
RECRUITING | NA |
| NCT06613425 |
Clinical Study of Combined Platelet Transfusion |
RECRUITING | PHASE4 |
| NCT06487247 |
HEME Home Transfusion Program |
RECRUITING | NA |
